Clinical TrialJun 18, 2026, 09:02 AM
AIM ImmunoTech Doses Final Subject in Phase 2 DURIPANC Trial; Results Q1 2027
AI Summary
AIM ImmunoTech Inc. announced that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial, evaluating Ampligen in combination with AstraZeneca’s Imfinzi for metastatic pancreatic cancer. Primary endpoint analysis is expected to begin in December 2026, with topline results anticipated in Q1 2027. Secondary endpoint analysis, including Overall Survival (OS), is expected to start in June 2027. The company plans to use exploratory biomarker data from DURIPANC to design a Phase 3 study, focusing on identifying patient subsets most likely to benefit from Ampligen-based therapy, building on promising prior data.
Key Highlights
- AIM ImmunoTech announced the final subject received their first dose in the Phase 2 DURIPANC clinical trial.
- The trial evaluates Ampligen with Imfinzi for metastatic pancreatic cancer.
- Primary Endpoint analysis is anticipated to begin in December 2026.
- Topline results for the DURIPANC trial are anticipated in Q1 2027.
- Secondary Endpoints analysis is expected to begin in June 2027.
- Previous data (NLR < 4.5) showed OS of 34.8 months vs 12.5 months for historical controls.
- Previous data (CA 19-9 < 1000) showed OS of 24.1 months vs 12.5 months for historical controls.
- The company aims to use biomarker data to design a Phase 3 study for
- super-responder
- patient subsets.
Price Impact
More from AIM